<DOC>
	<DOCNO>NCT00653822</DOCNO>
	<brief_summary>The objective study compare pharmacokinetic pharmacodynamic property safety profile alefacept Caucasian Japanese healthy subject</brief_summary>
	<brief_title>A Study Pharmacokinetics Safety Alefacept Caucasian Japanese Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Alefacept</mesh_term>
	<criteria>Caucasian Japanese healthy subject body mass index ( BMI ) 18 29 kg/m2 , inclusive Japanese subject first generation , bear Japan parent Japanese decent , reside outside Japan 5 year less OR Caucasian subject Hispanic nonHispanic , born parent European decent ( Mestizo mixed race ) Subject must clinical laboratory test result within normal therapeutic range , abnormal , result clinically significant determine investigator CD4+ lymphocyte count outside normal limit Screening Received vaccine within 60 day prior study drug administration History drug alcohol abuse within 2 year prior study drug administration Treatment systemic immunosuppressant agent within 6 month prior study drug administration Treatment antibody biologic product within 6 month prior study drug administration Treatment systemic steroid steroid inhaler within 2 month prior study drug administration A smoking habit great 10 cigarette day</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Amevive</keyword>
	<keyword>alefacept</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Japanese</keyword>
</DOC>